Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer | |
Zhu, A.; Yuan, P.; Wang, J.; Fan, Y.; Luo, Y.; Cai, R.; Zhang, P.; Li, Q.; Ma, F.; Xu, B. | |
2019 | |
卷号 | 79期号:4 |
ISSN号 | 0008-5472 |
DOI | 10.1158/1538-7445.SABCS18-P2-10-01 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6337475 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Zhu, A.,Yuan, P.,Wang, J.,et al. Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer[J],2019,79(4). |
APA | Zhu, A..,Yuan, P..,Wang, J..,Fan, Y..,Luo, Y..,...&Xu, B..(2019).Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer.,79(4). |
MLA | Zhu, A.,et al."Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer".79.4(2019). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论